2014-17912. New Animal Drugs; Bacitracin Methylene Disalicylate; Dinoprost Solution; Gonadorelin Hydrochloride; Progesterone Intravaginal Inserts; Salinomycin; Ractopamine; Tylosin
-
Start Preamble
Start Printed Page 44277
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule; technical amendment.
SUMMARY:
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during June 2014. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to remove a cross-reference to a combination drug medicated feed that is no longer codified.
DATES:
This rule is effective July 31, 2014.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, george.haibel@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during June 2014 as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the Center for Veterinary Medicine (CVM) FOIA Electronic Reading Room: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm. Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/default.htm.
Also, the regulations are being amended in 21 CFR 558.76 to remove a cross-reference to a combination drug medicated feed which was removed in earlier corrections to part 558 (79 FR 10976, February 27, 2014). This amendment is being made to improve the accuracy of the regulations.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
Start List of Subjects Start Printed Page 44278Table 1—Original and Supplemental NADAs and ANADAs Approved During June 2014
NADA/ ANADA Sponsor New animal drug product name Action 21 CFR Sections FOIA Summary NEPA Review 108-901 Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 LUTALYSE (dinoprost injection) Injection Supplemental approval of label references to approved uses with gonadorelin hydrochloride injection and progesterone intravaginal inserts 522.690, 522.1077, 529.1940 yes CE1 2 128-686 Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 BIO-COX 60 (salinomycin sodium) Type A medicated article Supplemental approval of revised assay limits for Type A medicated articles 558.4 no CE1 2 200-473 3 Huvepharma AD, 5th Floor, 3A, Nikolay Haytov Str., 1113 Sophia, Bulgaria TYLOVET (tylosin tartrate) Soluble Supplemental approval of a change in marketing status from over-the-counter (OTC) to by veterinary prescription (Rx) 520.2640 no CE1 2 200-560 Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 ACTOGAIN (ractopamine HCl), RUMENSIN (monensin), MGA (melengestrol acetate), and Type B and C medicated feeds Original approval as a generic copy of NADA 141-234 558.500 yes CE1 2 200-562 Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 ACTOGAIN (ractopamine HCl), RUMENSIN (monensin), TYLAN (tylosin phosphate), and MGA (melengestrol acetate) Type B and C medicated feeds Original approval as a generic copy of NADA 141-233 558.500 yes CE1 2 1 The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not individually or cumulatively have a significant effect on the human environment. 2 CE granted under 21 CFR 25.33(a)(1). 3 The application listed was identified as being affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209”, December 2013. List of Subjects
21 CFR Parts 520, 522, and 529
- Animal drugs
21 CFR Part 558
- Animal drugs
- Animal feeds
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 520, 522, 529, and 558 are amended as follows:
Start PartPART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part1. The authority citation for 21 CFR part 520 continues to read as follows:
End Amendment Part[Amended]2. In § 520.2640, in paragraphs (b)(1) and (d) remove “No. 000986” and in its place add “Nos. 000986 and 016592”; and in paragraph (b)(2) remove “Nos. 016592 and 061623” and in its place add “No. 061623”.
End Amendment Part Start PartPART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part3. The authority citation for 21 CFR part 522 continues to read as follows:
End Amendment Part Start Amendment Part4. In § 522.690, revise the section heading and paragraph (d)(2)(v) to read as follows:
End Amendment PartDinoprost.* * * * *(d) * * *
(2) * * *
(v) Dinoprost injection as provided by No. 054771 in § 510.600(c) of this chapter may also be used concurrently with gonadorelin hydrochloride injection as in § 522.1077 and with progesterone intravaginal inserts as in § 529.1940 of this chapter.
* * * * *5. In § 522.1077, revise paragraph (c)(1)(ii) to read as follows:
End Amendment PartGonadorelin hydrochloride.* * * * *(c) * * *
(1) * * *
(ii) For use with dinoprost injection to synchronize estrous cycles to allow fixed-time artificial insemination (FTAI) in lactating dairy cows, administer to each cow 100 to 200 mcg gonadorelin by intramuscular injection, followed 6 to 8 days later by 25 mg dinoprost by intramuscular injection, followed 30 to 72 hours later by 100 to 200 mcg gonadorelin by intramuscular injection. Dinoprost injection as in § 522.690, provided by No. 054771 in § 510.600(c) of this chapter.
* * * * *PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part6. The authority citation for 21 CFR part 529 continues to read as follows:
End Amendment Part Start Amendment Part7. In § 529.1940, revise paragraph (d), the second sentence in paragraph (e)(1)(i) and the last sentence in paragraph (e)(1)(iii) to read as follows:
End Amendment PartProgesterone intravaginal inserts.* * * * *(d) Special considerations. Product labeling shall bear the following warning: “Avoid contact with skin by wearing protective gloves when handling inserts. Store removed inserts in a sealable container until they can be disposed of in accordance with applicable local, state, and Federal regulations.”
(e) * * *
(1) * * *
(i) * * * When used for indications listed in paragraph (e)(1)(ii)(A) of this section, administer 25 mg dinoprost as a single intramuscular injection 1 day prior to insert removal (Day 6). * * *
* * * * *(iii) * * * Dinoprost injection for use in paragraphs (e)(1)(ii)(A) and (e)(1)(ii)(B) of this section as in § 522.690 of this chapter, provided by No. 054771 in § 510.600(c) of this chapter.
* * * * *PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
End Part Start Amendment Part8. The authority citation for 21 CFR part 558 continues to read as follows:
End Amendment Part[Amended]9. In paragraph (d) of § 558.4, in the “Category I” table, in the “Assay limits percent type A” column, in the entry for “Salinomycin”, remove “95-115” and in its place add “90-110”.
End Amendment Part[Amended]10. In § 558.76, remove and reserve paragraph (d)(3)(vii).
End Amendment Part[Amended]11. In § 558.500, in the table in paragraphs (e)(2)(viii) and (e)(2)(x), in the “Sponsor” column, remove “000986” and in its place add “000986, 054771”.
End Amendment Part Start SignatureDated: July 24, 2014.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2014-17912 Filed 7-30-14; 8:45 am]
BILLING CODE 4164-01-P
Document Information
- Effective Date:
- 7/31/2014
- Published:
- 07/31/2014
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final rule; technical amendment.
- Document Number:
- 2014-17912
- Dates:
- This rule is effective July 31, 2014.
- Pages:
- 44277-44278 (2 pages)
- Docket Numbers:
- Docket No. FDA-2014-N-0002
- Topics:
- Animal drugs, Animal feeds
- PDF File:
- 2014-17912.pdf
- Supporting Documents:
- » FREEDOM OF INFORMATION SUMMARY ANADA 200-512 TRIAMULOX tiamulin hydrogen fumarate, 12.3% Liquid Concentrate Swine re New Animal Drugs; Approval of New Animal Drug Applications; Change of Sponsor
- » FREEDOM OF INFORMATION SUMMARY NADA 034-267 GENTOCIN DURAFILM (Gentamicin Sulfate and Betamethasone) Sterile Ophthalmic Solution re New Animal Drugs; Approval of New Animal Drug Applications; Change of Sponsor
- » FREEDOM OF INFORMATION SUMMARY NADA 141-349 DRAXXIN 25 Injectable Solution Tulathromycin Injection Cattle (suckling calves, dairy calves, and veal calves) re New Animal Drugs; Approval of New Animal Drug Applications; Change of Sponsor
- » FREEDOM OF INFORMATION SUMMARY NADA 141-276 ZILMAX plus RUMENSIN plus TYLAN (zilpaterol hydrochloride 4.8%; monensin, USP; and tylosin phosphate) Type A Medicated Articles For Use in the Manufacture of Type B and C Medicated Feeds Cattle Fed in Confinemen
- » FREEDOM OF INFORMATION SUMMARY NADA 141-258 ZILMAX Zilpaterol Hydrochloride 4.8% Type A medicated article to be used in the manufacture of Type B and C medicated feeds Cattle fed in confinement for slaughter re New Animal Drugs; Approval of New Animal Dru
- » FREEDOM OF INFORMATION SUMMARY NADA 141-232 SIMPLICEF Cefpodoxime proxetil Chewable tablets Dogs re New Animal Drugs; Approval of New Animal Drug Applications; Change of Sponsor
- » FREEDOM OF INFORMATION SUMMARY NADA 141-068 BAYTRIL 100 Injectable Solution Enrofloxacin Swine re New Animal Drugs; Approval of New Animal Drug Applications; Change of Sponsor
- » FREEDOM OF INFORMATION SUMMARY NADA 141-034 GAINPRO bambermycins Type A Medicated Article to be used in the manufacture of Type C Medicated Feeds Pasture cattle (slaughter, stocker, and feeder cattle, and dairy and beef replacement heifers) re New Animal
- » FREEDOM OF INFORMATION SUMMARY NADA 141-437 OSURNIA florfenicol, terbinafine, betamethasone acetate Otic gel Dogs re New Animal Drugs; Approval of New Animal Drug Applications; Change of Sponsor
- » FREEDOM OF INFORMATION SUMMARY ANADA 200-575 Carprofen Chewable Tablets Carprofen Dogs re New Animal Drugs; Approval of New Animal Drug Applications; Change of Sponsor
- CFR: (7)
- 21 CFR 520.2640
- 21 CFR 522.690
- 21 CFR 522.1077
- 21 CFR 529.1940
- 21 CFR 558.4
- More ...